JPM downgrades Neumora, cites risk of more negative trial news
JPMorgan Downgrades Neumora Therapeutics to Underweight, Flags More Trial Setbacks on Horizon New York, September 16, 2025 — Biotech stocks can be a rollercoaster, and Neumora Therapeutics (NMRA) just hit a sharp dip. JPMorgan Chase analysts pulled no punches Tuesday, slashing their rating on the neuroscience upstart from Neutral to Underweight while warning of fresh … Read more